Journal Article
. 2018 Mar;36(14).
doi: 10.1200/JCO.2017.76.8861.

Molecular Characterization and Mortality From Breast Cancer in Men

Suleiman Alfred Massarweh 1 George W Sledge 1 Dave P Miller 1 Debbie McCullough 1 Valentina I Petkov 1 Steven Shak 1 
Affiliations
  • PMID: 29584547
  •     29 References
  •     14 citations

Abstract

Purpose Limited data exist on the molecular biology, treatment, and outcomes of breast cancer in men, and much of our understanding in this area remains largely an extrapolation from data in women with breast cancer. Materials and Methods We studied men and women with hormone receptor-positive breast cancer and the 21-gene Breast Recurrence Score (RS) results. Differences in clinical characteristics and gene expression were determined, and distribution of RS results was correlated with 5-year breast cancer-specific survival (BCSS) and overall survival. Results There were 3,806 men and 571,115 women. Men were older than women (mean age, 64.2 v 59.1 years; P < .001). RS < 18 predominated in both genders, but RS ≥ 31 was more frequent in men (12.4% v 7.4%; P < .001), as were very low scores (RS < 11; 33.8% v 22.1%; P < .001). Mean gene expression was higher in men for the estrogen receptor (ER), proliferation, and invasion groups. ER was lowest and progesterone receptor was highest in women younger than 50 years of age, with a progressive increase in ER with age. Men younger than 50 years of age had slightly lower ER and progesterone receptor compared with older men. Survival data were available from SEER for 322 men and 55,842 women. Five-year BCSS was 99.0% (95% CI, 99.3% to 99.9%) and 95.9% (95% CI, 87.6% to 98.7%) for men with RS < 18 and RS 18-30, respectively, and for women, it was 99.5% (95% CI, 99.4% to 99.6%) and 98.6% (95% CI, 98.4% to 98.8%), respectively. RS ≥ 31 was associated with an 81.0% 5-year BCSS in men (95% CI, 53.3% to 93.2%) and 94.9% 5-year BCSS (95% CI, 93.9% to 95.7%) in women. Five-year BCSS and overall survival were lower in men than in women. Conclusion This study reveals some distinctive biologic features of breast cancer in men and an important prognostic role for RS testing in both men and women.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Male breast cancer: risk factors, diagnosis, and management (Review).
Katherine A Johansen Taber, Lee R Morisy, Albert J Osbahr, Barry D Dickinson.
Oncol Rep, 2010 Sep 30; 24(5). PMID: 20878100
Review.
Male breast cancer: a population-based comparison with female breast cancer.
William F Anderson, Ismail Jatoi, Julia Tse, Philip S Rosenberg.
J Clin Oncol, 2009 Dec 10; 28(2). PMID: 19996029    Free PMC article.
Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
Abeer Alqaisi, Li Chen, +5 authors, Suleiman Massarweh.
Breast Cancer Res Treat, 2014 Sep 27; 148(2). PMID: 25257728
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Holm Eggemann, Atanas Ignatov, +5 authors, Serban-Dan Costa.
Breast Cancer Res Treat, 2012 Dec 12; 137(2). PMID: 23224235
Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration.
Jennifer L Gnerlich, Anjali D Deshpande, +3 authors, Julie A Margenthaler.
Ann Surg Oncol, 2011 Apr 13; 18(7). PMID: 21484520    Free PMC article.
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Payal D Shah, Sujata Patil, +3 authors, Mark E Robson.
Cancer, 2016 Feb 10; 122(8). PMID: 26859126
Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
Naama Halpern, Amir Sonnenblick, +5 authors, Luna Kadouri.
Int J Cancer, 2017 Jan 26; 140(9). PMID: 28120435
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Tumor characteristics and clinical outcome of elderly women with breast cancer.
S G Diab, R M Elledge, G M Clark.
J Natl Cancer Inst, 2000 Apr 06; 92(7). PMID: 10749910
Highly Cited.
Male breast cancer according to tumor subtype and race: a population-based study.
Mariana Chavez-Macgregor, Christina A Clarke, +2 authors, Sharon H Giordano.
Cancer, 2013 Jan 24; 119(9). PMID: 23341341    Free PMC article.
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Valentina Silvestri, Daniel Barrowdale, +146 authors, Laura Ottini.
Breast Cancer Res, 2016 Feb 10; 18(1). PMID: 26857456    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
The Genomic Landscape of Male Breast Cancers.
Salvatore Piscuoglio, Charlotte K Y Ng, +19 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2016 Mar 11; 22(16). PMID: 26960396    Free PMC article.
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Mary Pritzlaff, Pia Summerour, +8 authors, Holly LaDuca.
Breast Cancer Res Treat, 2016 Dec 23; 161(3). PMID: 28008555    Free PMC article.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Gottfried Konecny, Giovanni Pauletti, +12 authors, Dennis J Slamon.
J Natl Cancer Inst, 2003 Jan 17; 95(2). PMID: 12529347
Highly Cited.
Comparison of SEER Treatment Data With Medicare Claims.
Anne-Michelle Noone, Jennifer L Lund, +4 authors, Joan L Warren.
Med Care, 2014 Mar 19; 54(9). PMID: 24638121    Free PMC article.
Highly Cited.
Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.
T F Anelli, A Anelli, +2 authors, P I Borgen.
Cancer, 1994 Jul 01; 74(1). PMID: 8004585
Breast cancer: trends in international incidence in men and women.
E Kreiter, A Richardson, J Potter, Y Yasui.
Br J Cancer, 2014 Feb 13; 110(7). PMID: 24518595    Free PMC article.
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
R Lewin, A Sulkes, +11 authors, R Yerushalmi.
Breast Cancer Res Treat, 2016 May 27; 157(3). PMID: 27225387
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Yu Chuan Tai, Susan Domchek, Giovanni Parmigiani, Sining Chen.
J Natl Cancer Inst, 2007 Nov 29; 99(23). PMID: 18042939    Free PMC article.
Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.
Yuan Chun Ding, Linda Steele, +2 authors, Susan L Neuhausen.
Breast Cancer Res Treat, 2010 Oct 12; 126(3). PMID: 20927582    Free PMC article.
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
Laura Ottini, Valentina Silvestri, +17 authors, Domenico Palli.
Breast Cancer Res Treat, 2012 Apr 25; 134(1). PMID: 22527108
Improved estimates of cancer-specific survival rates from population-based data.
Nadia Howlader, Lynn A G Ries, +3 authors, Kathleen A Cronin.
J Natl Cancer Inst, 2010 Oct 13; 102(20). PMID: 20937991    Free PMC article.
Highly Cited.
Breast carcinoma in men: a population-based study.
Sharon H Giordano, Deborah S Cohen, +2 authors, Gabriel N Hortobagyi.
Cancer, 2004 Jun 29; 101(1). PMID: 15221988
Highly Cited.
Cancer statistics, 2016.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2016 Jan 09; 66(1). PMID: 26742998
Highly Cited.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.
Linda C Harlan, Jo Anne Zujewski, Marc T Goodman, Jennifer L Stevens.
Cancer, 2010 Jun 22; 116(15). PMID: 20564105    Free PMC article.
Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.
Patricia A Cronin, Anya Romanoff, +7 authors, Mary L Gemignani.
Ann Surg Oncol, 2018 Oct 10; 25(13). PMID: 30298320    Free PMC article.
Overall Mortality After Diagnosis of Breast Cancer in Men vs Women.
Fei Wang, Xiang Shu, +6 authors, Xiao-Ou Shu.
JAMA Oncol, 2019 Sep 20;. PMID: 31536134    Free PMC article.
Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review.
Ang Zheng, Lin Zhang, +2 authors, Feng Jin.
Am J Mens Health, 2019 May 10; 13(3). PMID: 31068065    Free PMC article.
Review.
Incidence and survival outcomes of early male breast cancer: a population-based comparison with early female breast cancer.
Yan Wang, Kai Chen, +6 authors, Shunrong Li.
Ann Transl Med, 2019 Dec 07; 7(20). PMID: 31807518    Free PMC article.
High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer.
Si-Qi Qiu, Johan van Rooijen, +8 authors, Carolien P Schröder.
Breast Cancer Res, 2020 Mar 20; 22(1). PMID: 32188473    Free PMC article.
Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis.
Sarah B Bateni, Anders J Davidson, +5 authors, Candice A M Sauder.
Ann Surg Oncol, 2019 Feb 15; 26(7). PMID: 30761438    Free PMC article.
Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls.
Joseph Liu, Anupama Suresh, +18 authors, Robert Wesolowski.
Eur J Breast Health, 2020 Jul 14; 16(3). PMID: 32656521    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Review.
Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
Fei Wang, Sonya Reid, +6 authors, Xiao-Ou Shu.
Clin Cancer Res, 2019 Nov 22; 26(1). PMID: 31748278    Free PMC article.
Predicting Survival Benefit of Sparing Sentinel Lymph Node Biopsy in Low-Risk Elderly Patients With Early Breast Cancer: A Population-Based Analysis.
Li Xu, Nan Wen, +5 authors, Qing Lv.
Front Oncol, 2020 Oct 13; 10. PMID: 33042815    Free PMC article.
The Regulatory Role of Mitochondrial MicroRNAs (MitomiRs) in Breast Cancer: Translational Implications Present and Future.
Miguel A Ortega, Oscar Fraile-Martínez, +6 authors, Ángel Asúnsolo.
Cancers (Basel), 2020 Sep 03; 12(9). PMID: 32872155    Free PMC article.
Review.
A spontaneous unveiling of bilateral DCIS in an elderly male.
Tessa Meyer, Patrick Borgen, Kristen Rojas.
J Surg Case Rep, 2020 Nov 07; 2020(10). PMID: 33154807    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.
Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Jin-Li Wei, Jia-Xin Zhang, De-Yuan Fu.
World J Surg Oncol, 2018 Dec 19; 16(1). PMID: 30558615    Free PMC article.